Pediatrix Medical Group (NYSE:MD) Upgraded by StockNews.com to Hold

Pediatrix Medical Group (NYSE:MDGet Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

A number of other analysts have also issued reports on the company. Deutsche Bank Aktiengesellschaft upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 price objective on the stock in a research note on Friday, June 7th. Truist Financial reiterated a “hold” rating and issued a $10.00 target price on shares of Pediatrix Medical Group in a research note on Wednesday, May 15th. Six equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $9.10.

Check Out Our Latest Stock Report on MD

Pediatrix Medical Group Stock Performance

Pediatrix Medical Group stock traded up $0.02 during trading on Wednesday, hitting $6.79. The stock had a trading volume of 487,310 shares, compared to its average volume of 1,003,840. The company has a quick ratio of 1.72, a current ratio of 1.72 and a debt-to-equity ratio of 0.81. The stock’s 50 day moving average is $7.60 and its two-hundred day moving average is $8.71. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $15.02. The stock has a market cap of $570.96 million, a price-to-earnings ratio of -7.98, a price-to-earnings-growth ratio of 1.38 and a beta of 1.56.

Pediatrix Medical Group (NYSE:MDGet Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.02. Pediatrix Medical Group had a positive return on equity of 10.31% and a negative net margin of 3.53%. The business had revenue of $495.10 million for the quarter, compared to analysts’ expectations of $496.25 million. As a group, analysts predict that Pediatrix Medical Group will post 1.13 EPS for the current year.

Hedge Funds Weigh In On Pediatrix Medical Group

Hedge funds and other institutional investors have recently modified their holdings of the company. Pacer Advisors Inc. grew its position in Pediatrix Medical Group by 126.9% during the fourth quarter. Pacer Advisors Inc. now owns 3,235,729 shares of the company’s stock valued at $30,092,000 after acquiring an additional 1,809,828 shares during the last quarter. Boston Partners purchased a new position in Pediatrix Medical Group in the 4th quarter worth $12,452,000. Invenomic Capital Management LP lifted its stake in Pediatrix Medical Group by 93.3% in the fourth quarter. Invenomic Capital Management LP now owns 1,377,951 shares of the company’s stock worth $12,815,000 after purchasing an additional 664,955 shares during the last quarter. Clark Estates Inc. NY purchased a new stake in Pediatrix Medical Group during the fourth quarter valued at about $3,302,000. Finally, Smith Graham & Co. Investment Advisors LP grew its stake in shares of Pediatrix Medical Group by 51.5% during the fourth quarter. Smith Graham & Co. Investment Advisors LP now owns 534,621 shares of the company’s stock valued at $4,972,000 after buying an additional 181,662 shares during the last quarter. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

Pediatrix Medical Group Company Profile

(Get Free Report)

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

Recommended Stories

Analyst Recommendations for Pediatrix Medical Group (NYSE:MD)

Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.